MSB Medical School Berlin, Rüdesheimer Str. 50, 14197, Berlin, Germany.
Sci Rep. 2024 Sep 12;14(1):21311. doi: 10.1038/s41598-024-69866-7.
Obesity is a major public health problem worldwide. Different approaches are known to face this problem, for example, dieting, surgery, or drug interventions. It has also been shown that placebos may help to reduce weight and hunger feelings, but the use of placebos is linked to problems with respect to the patient-healthcare-provider relationship. However, recent studies demonstrated that even placebos without deception (open-label placebos) affect symptoms such as pain, anxiety, or emotional distress. Here we aimed to examine whether an open-label placebo may help to lose weight in obesity. Our study included fifty-seven overweight and obese patients who aimed to lose weight using a combination of diet and sports. Patients were randomly divided into two groups. Participants in the open-label placebo group received two placebos each day. A treatment-as-usual group received no pills. Primary outcome included changes of body weight. Secondary outcomes were change of eating behavior and self-management abilities. After 4 weeks we found that participants in the open-label placebo condition lost more weight than the treatment-as-usual group. Furthermore, OLP treatment affected eating behavior. No effects for self-management abilities were found. Although further research is necessary, open-label placebos might help individuals to lose weight.
肥胖是全球范围内的一个主要公共卫生问题。人们已经知道了多种方法来应对这个问题,例如节食、手术或药物干预。此外,研究还表明,安慰剂可能有助于减轻体重和饥饿感,但安慰剂的使用与医患关系问题有关。然而,最近的研究表明,即使是没有欺骗成分的安慰剂(开放性安慰剂)也会影响疼痛、焦虑或情绪困扰等症状。在这里,我们旨在研究开放性安慰剂是否有助于肥胖者减肥。我们的研究纳入了 57 名超重和肥胖患者,他们希望通过饮食和运动相结合来减肥。患者被随机分为两组。开放性安慰剂组的参与者每天服用两片安慰剂,常规治疗组则不服用任何药物。主要结局包括体重变化。次要结局包括饮食行为和自我管理能力的变化。4 周后,我们发现开放性安慰剂组的参与者体重下降幅度大于常规治疗组。此外,OLP 治疗还影响了饮食行为,但对自我管理能力没有影响。尽管还需要进一步的研究,但开放性安慰剂可能有助于个体减肥。